SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Aravive, Inc. ARAV NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Aravive, Inc. (ARAV) is a Biotechnology company in the Healthcare sector, currently trading at $0.04. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is ARAV = $0 (+523.4% upside).

Financials: revenue is $9M, +24.4%/yr average growth. Net income is $81M (loss), growing at -64.2%/yr. Net profit margin is -885.6% (negative). Gross margin is -632.6% (-462.5 pp trend).

Balance sheet: total debt is $6M against $11M equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 2.73 (strong liquidity). Debt-to-assets is 10.1%. Total assets: $62M.

Analyst outlook: 8 / 18 analysts rate ARAV as buy (44%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$0.25

▲ 523.44% Upside

Average Price Target

The 12-month price target for Aravive, Inc. is $0.25.

ARAV SharesGrow Score Overview

54/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 58/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 0/100

Gross margin is + market cap

FUTURE 52/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ARAV

ARAV trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

ARAV: +24.4%/yr revenue is, -64.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet ARAV: Debt-to-Equity (D/E) ratio 0.59 (moderate), Current ratio is 2.73 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

Analyst outlook: 8 / 18 analysts rate ARAV as buy (44%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

ARAV: Net profit margin is -885.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.04-2.46

Volume4.04M

Avg Volume (30D)2.24M

Market Cap$2.95M

Beta (1Y)2.19

Share Statistics

EPS (TTM)-2.22

Shares Outstanding$36.37M

IPO Date2014-03-21

Employees23

CEOFredric N. Eshelman

Financial Highlights & Ratios

Revenue (TTM)$9.14M

Gross Profit$-57.8M

EBITDA$-70.84M

Net Income$-80.92M

Operating Income$-70.84M

Total Cash$53.69M

Total Debt$6.27M

Net Debt$-47.42M

Total Assets$62.15M

Price / Earnings (P/E)-0

Price / Sales (P/S)0.32

Analyst Forecast

1Y Price Target$0.25

Target High$0.25

Target Low$0.25

Upside+523.4%

Rating ConsensusHold

Analysts Covering18

Buy 44% Hold 50% Sell 6%

Price Target Summary

Company Info

CountryUS

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS03890D1081

Price Chart

ARAV

Aravive, Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

0.04 52WK RANGE 2.46

People Also View

ASLAN Pharmaceuticals Limited

Autolus Therapeutics plc

Aeglea BioTherapeutics, Inc.

Magenta Therapeutics, Inc.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message